US Patent Issued to LUNELLA BIOTECH on Oct. 27 for "Alkyl-TPP compounds for mitochondria targeting and anti-cancer treatments" (Canadian Inventors)

ALEXANDRIA, Va., Oct. 27 -- United States Patent no. 12,773,418, issued on Oct. 27, was assigned to LUNELLA BIOTECH INC. (Ontario, Canada).

"Alkyl-TPP compounds for mitochondria targeting and anti-cancer treatments" was invented by Michael P. Lisanti (Ottawa) and Federica Sotgia (Ottawa).

According to the abstract* released by the U.S. Patent & Trademark Office: "Alkyl-triphenylphosphonium compounds having a saturated, linear alkyl chain of about 9 to about 18 carbons may be used as therapeutic agents to treat cancer. Demonstrative compound dodecyl-TPP (d-TPP) dose-dependently inhibits the propagation of breast cancer stem cells and targets the adherent "bulk" of cancer cells, by decreasing MCF-7 cell viability. Further, d-TPP potently in...